Cicogna A C, Brooks W W, Hayes J A, Robinson K G, Sen S, Conrad C H, Bing O H
School of Medicine-Botucatu-Brasil.
Mol Cell Biochem. 1997 Jan;166(1-2):45-54. doi: 10.1023/a:1006889126666.
Colchicine has been demonstrated to suppress the release of fibroblast growth factors, retard collagen formation and augment collagenase activity. Trials with colchicine in patients with hepatic fibrosis have suggested clinical benefit. The development of impaired myocardial function in the spontaneously hypertensive rat (SHR) is associated with a marked increase in myocardial fibrosis. The present study was carried out to test the hypothesis that chronic colchicine administration to the SHR would prevent the development of fibrosis and impaired myocardial performance. Colchicine (1 mg/l drinking water) was administered to male SHR and WKY rats from at age 13 months until 24 months or until evidence of heart failure was observed. Age-matched untreated SHR and colchicine treated and untreated WKY served as controls. At study, active and passive properties of isolated left ventricular muscle preparations were determined. Myocardial fibrosis was assessed by measuring hydroxyproline and histologic determination of interstitial cross-sectional area. Increases in LV hydroxyproline and interstitial area were found in untreated SHR relative to WKY; passive myocardial stiffness was increased and active muscle properties were depressed. In comparing colchicine treated vs untreated SHR, no differences in hydroxyproline, interstitial area or intrinsic myocardial function were found. In the WKY, colchicine increased myocardial interstitium and passive stiffness without changing hydroxyproline. Active myocardial function was not depressed. Thus, chronic colchicine administration neither attenuated the development of interstitial fibrosis nor prevented impaired myocardial function in the SHR. Colchicine treatment was associated with increased interstitium in WKY with increased passive myocardial stiffness.
秋水仙碱已被证明可抑制成纤维细胞生长因子的释放,延缓胶原蛋白形成并增强胶原酶活性。在肝纤维化患者中使用秋水仙碱的试验已显示出临床益处。自发性高血压大鼠(SHR)心肌功能受损的发展与心肌纤维化的显著增加有关。本研究旨在验证以下假设:对SHR长期给予秋水仙碱可预防纤维化的发展和心肌功能受损。从13月龄开始,给雄性SHR和WKY大鼠饮用含1 mg/l秋水仙碱的水,直至24月龄或直至观察到心力衰竭迹象。年龄匹配的未治疗SHR以及经秋水仙碱治疗和未治疗的WKY大鼠作为对照。在研究时,测定分离的左心室肌肉制剂的主动和被动特性。通过测量羟脯氨酸和组织学测定间质横截面积来评估心肌纤维化。与WKY相比,未治疗的SHR中左心室羟脯氨酸和间质面积增加;被动心肌僵硬度增加,主动肌肉特性降低。比较经秋水仙碱治疗和未治疗的SHR,发现羟脯氨酸、间质面积或心肌固有功能无差异。在WKY中,秋水仙碱增加了心肌间质和被动僵硬度,但未改变羟脯氨酸。主动心肌功能未降低。因此,长期给予秋水仙碱既不能减轻SHR间质纤维化的发展,也不能预防心肌功能受损。秋水仙碱治疗与WKY中间质增加以及被动心肌僵硬度增加有关。